Opportunity Mapping (2)

Challenge A private equity fund which had successfully invested in the advanced biologics CDMO space was considering entering the radiopharmaceuticals CDMO space through investment in an established...

Challenge A glycan biomarker research company with a proprietary platform offering biomarker discovery and characterization, diagnostic development and commercialization asked Alacrita to help them...

Challenge An early stage, European cell therapy company focused on developing novel off-the-shelf NK cell therapy solutions for the treatment of a variety of cancers had developed a platform...

Challenge A start-up US biotech developing a non-opioid analgesic drug and delivery device was preparing to raise its first round of external funding. They engaged Alacrita to help frame the target...

Challenge Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan...

Challenge A leading UK university and an executive agency of the DoH were collaboratively developing a rapid (30 min) bacterial ID and antimicrobial resistance test platform. The technology...

Challenge An international oncology drug development company is developing a bispecific product, currently in preclinical development. As an initial evaluation, our client wanted to understand the...

Challenge A radiopharmaceuticals CDMO with activities in a range of therapeutic and diagnostic compounds including development-stage and commercial products asked Alacrita to assess the landscape and...

Challenge A group of healthcare investors with a long track record in the industry, but no biotechnology or research background, were interested in licensing a university project aimed at bladder...

Challenge: A biotech company developing immunomodulatory therapies asked Alacrita to assess the possible applications of its lead product, particularly in the context of improving the efficacy of...

Challenge On behalf of an established Alacrita client, a publicly traded clinical stage biotechnology company with a cell therapy platform technology, we assessed the potential of a novel...

Challenge A clinical-stage biotech company had an ongoing Phase 1 program exploring a combination therapy in multiple cancer types. The company wished to validate the addition of cholangiocarcinoma...